DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Lupron" drug pipelines has been added to ResearchAndMarkets.com's offering.
Lupron (leuprolide; Takeda/AbbVie) is a gonadotropin-releasing hormone (GnRH) agonist which acts on the pituitary gland in the brain to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as "flare".
With continued use, GnRH agonists such as Lupron cause downregulation of GnRH receptors in the pituitary gland, generating a significant reduction in LH and follicle-stimulating hormone secretion. This has the effect of complete shutdown of testosterone production in the testes, resulting in chemical castration where levels of the hormone drop by up to 95% and tumor growth is significantly reduced.
Key Topics Covered:
Product Profiles
Lupron: Prostate cancer
List of Figures
Figure 1: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7fzxfb/lupron_global?w=4
